| 2026-09-01 | 8-K | Form 8-K, Item 8.01 |
| 2026-08-20 | Press release | bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026 |
| 2026-08-20 | 8-K | Form 8-K, Item 3.03 |
| 2026-08-18 | Press release | bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung |
| 2026-08-18 | 8-K | Form 8-K, Item 8.01 |
| 2026-08-14 | Press release | bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules |
| 2026-08-14 | 8-K | Form 8-K, Item 1.01 |
| 2026-08-13 | Press release | bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules |
| 2026-08-07 | Press release | bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung |
| 2026-08-07 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-31 | 8-K | Form 8-K, Item 3.01 |
| 2026-07-27 | Press release | bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratifica |
| 2026-07-27 | 8-K | Form 8-K, Item 8.01 |
| 2026-07-22 | Press release | bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and |
| 2026-07-22 | 8-K | Form 8-K, Item 8.01 |
| 2026-07-07 | Press release | bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues |
| 2026-07-07 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-30 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-22 | Press release | bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectiv |
| 2026-06-18 | Press release | bioAffinity Technologies Announces Closing of $3.2 Million Offering |
| 2026-06-18 | 8-K | Form 8-K, Item 1.01 |
| 2026-06-17 | Press release | bioAffinity Technologies Announces Pricing of $3.2 Million Offering |
| 2026-06-16 | Press release | bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedic |
| 2026-06-16 | SEC filing | Form S-1/A |
| 2026-06-16 | 8-K | Form 8-K, Item 8.01 |
| 2026-06-12 | SEC filing | Form S-1 |
| 2026-06-02 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-27 | Press release | bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods |
| 2026-05-27 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-12 | Press release | bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2 |
| 2026-05-12 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-11 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-08 | Press release | bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung |
| 2026-05-08 | 8-K | Form 8-K, Item 2.02 results |
| 2026-04-30 | 8-K | Form 8-K, Item 5.02 |
| 2026-04-30 | SEC filing | Form S-1 |
| 2026-04-14 | 8-K | Form 8-K, Item 8.01 |
| 2026-04-07 | Press release | bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detectio |
| 2026-04-07 | 8-K | Form 8-K, Item 8.01 |
| 2026-04-01 | Press release | bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026 |